NCT00320190 - Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Leukemia, Myeloid, Chronic

Interventions

DRUG

Imatinib

Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.

DRUG

Dasatinib

Dasatinib tablets administered orally at a dose of 100 mg once daily.

Trial Locations (27)

2060

Local Institution, Antwerp

6000

Local Institution, Charleroi

7006

Local Institution, Trondheim

10043

Local Institution, Orbassano (To)

13273

Local Institution, Marseille

30008

Local Institution, Murcia

31059

Local Institution, Toulouse

33380

Local Institution, Tampere

34295

Local Institution, Montpellier

35033

Local Institution, Rennes

67091

Local Institution, Strasbourg

69437

Local Institution, Lyon

70185

Local Institution, Örebro

75475

Local Institution, Paris

125167

Local Institution, Moscow

191024

Local Institution, Saint Petersburg

197022

Local Institution, Saint Petersburg

00029

Local Institution, Helsinki

04103

Local Institution, Leipzig

0027

Local Institution, Oslo

1649-035

Local Institution, Lisbon

221 85

Local Institution, Lund

751 85

Local Institution, Uppsala

G31 2ER

Local Institution, Glasgow

SE5 9RS

Local Institution, London

W12 ONN

Local Institution, London

LS9 7FT

Local Institution, Leeds